Targeting Autophagy in Cancer
By Jean M. Mulcahy Levy, C. Towers, A. Thorburn. Nature Reviews. Cancer, 2017
1,825 citations recorded by the source corpus.
Autophagy is a mechanism by which cellular material is delivered to lysosomes for degradation, leading to the basal turnover of cell components and providing energy and macromolecular precursors. Autophagy has opposing, context-dependent roles in cancer, and interventions to both stimulate and inhibit autophagy have been proposed as cancer therapies. This has led to the therapeutic targeting of autophagy in cancer to be sometimes viewed as controversial. In this Review, we suggest a way forwards for the effective targeting of autophagy by understanding the context-dependent roles of autophagy and by capitalizing on modern approaches to clinical trial design.
Subfields: Epidemiology, Pharmacology, Physiology
View Paper: https://www.semanticscholar.org/paper/c864f746fea5b1f047bf6e80ffb884d37a803f63
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “539 Accordingly, combined treatment using both MAPK and autophagy inhibitors represents one of the best options for treating various carcinomas.”
- Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy (2022, background): “Given the fact that autophagy may antagonize antitumor immune response, autophagy inhibitors may enhance the effectiveness of immunotherapy and overcome resistance to immunotherapy.(410) For example, CQ blocks autophagy-mediated degradation of MHCI complexes, which together with dual ICIs treatment ”